Novo Nordisk's Oral Semaglutide Hits the Mark in Landmark Pediatric Diabetes Trial
The PIONEER TEENS Phase 3 trial delivered statistically significant blood sugar improvements in children as young as 10 — and could bring the first pill-based GLP-1 therapy to young people with type 2 diabetes.
Novo Nordisk announced positive Phase 3 results for oral semaglutide in children and adolescents with type 2 diabetes, a milestone that could reshape treatment options for a growing population of young patients. The trial, known as PIONEER TEENS, tested the once-daily pill in patients ages 10 to 17 and met its primary endpoint with a statistically significant reduction in blood sugar compared to placebo.
What the Data Showed
The Phase 3a trial enrolled 132 children and adolescents already being treated with background therapies such as metformin, basal insulin, or both. Participants were randomized to one of three doses of oral semaglutide — 3 mg, 7 mg, or 14 mg — taken once daily, and followed for 26 weeks. Those on oral semaglutide saw a 0.83 percentage point greater reduction in HbA1c (a key marker of long-term blood sugar control) compared to those on placebo, a difference researchers called highly statistically significant (p<0.001). The safety and tolerability profile was consistent with what's been seen in adults taking semaglutide, with gastrointestinal side effects — nausea and stomach upset, most commonly — as the most frequently reported issues.
It's worth noting that this trial evaluated the oral form of semaglutide, currently marketed for adults with diabetes as Rybelsus (soon to be rebranded as "Ozempic Pill"), rather than Wegovy, the injectable version of semaglutide approved for weight management. Both share the same active ingredient, but the pediatric diabetes data specifically applies to the pill form under Novo's PIONEER development program. Novo Nordisk has also separately reported strong pediatric obesity results this year for the injectable formulation in its STEP Young trial, where 40.4% of children with obesity achieved a BMI below the obesity threshold — a related but distinct milestone in the company's youth-focused pipeline.
Why This Trial Matters
Type 2 diabetes in children and teenagers has been rising for years, and treatment options for this age group remain limited compared to what's available to adults. Until now, most GLP-1 receptor agonist therapies approved for pediatric type 2 diabetes have required injections, which can be a significant barrier for young patients and their families — logistically, emotionally, or both. If approved, oral semaglutide would become the first pill-based GLP-1 therapy available for adolescents with type 2 diabetes, offering a needle-free alternative that could improve adherence and quality of life for younger patients managing a chronic condition.
What's Next
Novo Nordisk said it plans to file for regulatory approval of oral semaglutide in pediatric type 2 diabetes with both the U.S. Food and Drug Administration and European regulators in the second half of 2026. If cleared, it would expand the company's pediatric diabetes portfolio, which already includes an approved version of Victoza (liraglutide) for children ages 10 to 17. Given the strength of the topline data, analysts expect the filing to move forward on the timeline Novo has outlined, though final approval will depend on regulators' full review of the safety and efficacy package.
Sources: Fierce Pharma: With trial win, Novo Nordisk eyes adolescent diabetes approval for oral semaglutide, BiotechReality: Novo Nordisk Oral Semaglutide for Type 2 Diabetes in Children, BioSpace: Novo Nordisk STEP Young Phase 3 Data